抗肿瘤药物致心脏损伤的药物防治进展  

Advances in the prevention and treatment of cardiotoxicity caused by anti-tumor drugs

作　　者：邰宵辉 张玲芳[1] 党春艳 张旭霞[1] 薛丽[1] 刘乐[1] 李红玲[1] TAI Xiaohui;ZHANG Lingfang;DANG Chunyan;ZHANG Xuxia;XUE Li;LIU Le;LI Hongling(Department of Oncology,Gansu Provincial People's Hospital,Lanzhou 730013,China)

机构地区：[1]甘肃省人民医院肿瘤内科,兰州730013

出　　处：《临床肿瘤学杂志》2023年第1期70-76,共7页Chinese Clinical Oncology

基　　金：国家自然科学基金项目(81560498);甘肃省科技厅国际合作项目(20YF8WA096);甘肃省自然科学基金项目(21JR11RA191)。

摘　　要：随着恶性肿瘤治疗手段的改进,抗肿瘤药物如化疗、靶向治疗、内分泌治疗及生物免疫制剂等相关心脏损伤已经成为肿瘤患者长期生存的难题,严重影响患者生活质量。在某些肿瘤人群中,心血管死亡的长期风险已经超过了癌症死亡的风险。为了降低心血管疾病的风险,人们对在抗肿瘤治疗开始时使用心脏保护策略越来越重视。相关研究表明右丙亚胺、神经激素拮抗剂、腺苷酸活化蛋白激酶(AMPK)激活剂等可干预抗肿瘤治疗相关心脏损伤,现对最近完成的以及正在进行的抗肿瘤药物致心脏损伤药物防治的临床试验的证据进行评价并作一综述。With the improvement in the treatment of malignant tumors, anti-tumor drugs such as chemotherapy, targeted therapy, endocrine therapy and biological immune agents related to heart damage have become a challenge for long-term survival of cancer patients, seriously affecting the quality of life of patients. In some tumor populations, the long-term risk of cardiovascular death has exceeded the risk of cancer death. To reduce the risk of cardiovascular disease, there is increasing emphasis on the use of cardioprotective strategies at the start of anti-tumor treatment. Relevant studies have shown that dexamethasone, neurohormone antagonists, adenosine phosphate-activated protein kinase(AMPK) activators can interfere with cardiac injury related to anti-tumor therapy. Evidence from recently completed and ongoing clinical trials of antineoplastic drugs for the prevention and treatment of cardiotoxicity is reviewed.

关 键 词：抗肿瘤药物 心脏损伤 防治 研究进展 

分 类 号：R730[医药卫生—肿瘤]